
Opinion|Videos|May 29, 2024
Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Gedatolisib for HR+, HER2-Negative Advanced Breast Cancer
2
Unique Pharmacy Technician Career Ladder Meets the Needs of a Growing Profession
3
Circulating Tumor Cells May Guide Use of Tarlatamab in Small Cell Lung Cancer
4
Key Considerations for Pharmacists on Hydroxyapatite Toothpaste Tablets
5






















































































































































































































